To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Type 2 Diabetes

Interventions

DRUG

AZD1656

Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.

DRUG

Placebo

Dosing to match AZD1656

Trial Locations (1)

Research Site, Chula Vista